CPHGF (Consun Pharmaceutical Group) DeferredTaxAndRevenue: $0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPHGF Consun Pharmaceutical Group Ltd CPHGF
71 GF Score
Price $1.80
GF Value $1.11
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Consun Pharmaceutical Group DeferredTaxAndRevenue?

Consun Pharmaceutical Group CPHGF +9.09% 71 DeferredTaxAndRevenue is $0.0 Mil as of Dec. 2025. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Consun Pharmaceutical Group's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.0 Mil.

Consun Pharmaceutical Group DeferredTaxAndRevenue Related Terms

Consun Pharmaceutical Group DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Consun Pharmaceutical Group's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Consun Pharmaceutical Group DeferredTaxAndRevenue Chart

Consun Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Consun Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CPHGF
71GF Score
Consun Pharmaceutical Group Ltd CPHGF
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.0 Mil mean?
Consun Pharmaceutical Group (CPHGF) has a DeferredTaxAndRevenue of $0.0 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Consun Pharmaceutical Group.
Is Consun Pharmaceutical Group's DeferredTaxAndRevenue too high?
Consun Pharmaceutical Group's current DeferredTaxAndRevenue is $0.0 Mil. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's DeferredTaxAndRevenue compare to ZTS and UTHR?
Consun Pharmaceutical Group's DeferredTaxAndRevenue of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Drug Manufacturers company?
A good DeferredTaxAndRevenue depends on the Drug Manufacturers industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Consun Pharmaceutical Group. Consun Pharmaceutical Group's current DeferredTaxAndRevenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current DeferredTaxAndRevenue is $0.0 Mil. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current DeferredTaxAndRevenue is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11. GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.

Key valuation signals for CPHGF:

  • DeferredTaxAndRevenue: $0.0 Mil
  • GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Consun Pharmaceutical Group Business Description

Other Exchanges 01681:Hong KongC1P:Germany
Address 71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score

Get the complete analysis for CPHGF

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$1.11
GF Value